Since I started this topic I feel its incumbent on me to say a few words on this stopic. I hope bear does not mind.

Vascepa is theoretically acting by changing the epa/aa ratio which is a measure of cellular inflammation. For a link showing how this affects cvs and diabetes, one good article is  http://care.diabetesjournals.org/content/37/1/e7

There are several articles particularly in the Japanese literature on the Jelis study, which is the precursor of the vascepa study explaining the decrease in cellular inflammation as mechanism of modulating cvs pathology, if anyone wants to research.

The fact that with RVx we are targeting patients with increased cpr and metabolic syndrome suggests we are targeting the same patient base. As bear explained there is considerable evidence re reduction of cellular inflammation by rvx drug.